Abstract: Daridorexant improved night and daytime symptoms of insomnia disorder in two parallel, phase 3, 12-week studies with maintained improvements over a 40-week extension study. The ...
Abstract: As insomnia affects elderly more than younger adults, therapeutic options with limited safety risks are needed to treat this patient group. We report elderly subgroup analyses f...